JP2019503387A - 抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 - Google Patents

抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 Download PDF

Info

Publication number
JP2019503387A
JP2019503387A JP2018539118A JP2018539118A JP2019503387A JP 2019503387 A JP2019503387 A JP 2019503387A JP 2018539118 A JP2018539118 A JP 2018539118A JP 2018539118 A JP2018539118 A JP 2018539118A JP 2019503387 A JP2019503387 A JP 2019503387A
Authority
JP
Japan
Prior art keywords
antibody
nivolumab
antigen
dose
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018539118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503387A5 (2
Inventor
ネイサン・フェイス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019503387A publication Critical patent/JP2019503387A/ja
Publication of JP2019503387A5 publication Critical patent/JP2019503387A5/ja
Priority to JP2021210901A priority Critical patent/JP2022046649A/ja
Priority to JP2024108149A priority patent/JP2024133611A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018539118A 2016-01-27 2017-01-27 抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 Pending JP2019503387A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021210901A JP2022046649A (ja) 2016-01-27 2021-12-24 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法
JP2024108149A JP2024133611A (ja) 2016-01-27 2024-07-04 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287717P 2016-01-27 2016-01-27
US62/287,717 2016-01-27
PCT/US2017/015333 WO2017132508A1 (en) 2016-01-27 2017-01-27 Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021210901A Division JP2022046649A (ja) 2016-01-27 2021-12-24 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法

Publications (2)

Publication Number Publication Date
JP2019503387A true JP2019503387A (ja) 2019-02-07
JP2019503387A5 JP2019503387A5 (2) 2020-03-05

Family

ID=58163189

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018539118A Pending JP2019503387A (ja) 2016-01-27 2017-01-27 抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法
JP2021210901A Pending JP2022046649A (ja) 2016-01-27 2021-12-24 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法
JP2024108149A Pending JP2024133611A (ja) 2016-01-27 2024-07-04 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021210901A Pending JP2022046649A (ja) 2016-01-27 2021-12-24 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法
JP2024108149A Pending JP2024133611A (ja) 2016-01-27 2024-07-04 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法

Country Status (6)

Country Link
US (3) US20210206854A1 (2)
EP (1) EP3408296A1 (2)
JP (3) JP2019503387A (2)
KR (1) KR20180101584A (2)
CN (1) CN108602892A (2)
WO (1) WO2017132508A1 (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
JP2018514550A (ja) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
EP4458417A3 (en) 2015-08-11 2025-02-19 Wuxi Biologics Ireland Limited Novel anti-pd-1 antibodies
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
SMT202500282T1 (it) 2015-11-18 2025-09-12 Bristol Myers Squibb Co Trattamento del cancro del polmone utilizzando una combinazione di un anticorpo anti-pd-1 e di un anticorpo anti-ctla-4
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
WO2019157124A1 (en) * 2018-02-08 2019-08-15 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
KR102673786B1 (ko) 2018-08-28 2024-06-07 주식회사 엘지에너지솔루션 원통형 전지 및 이의 제조 방법
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
CN113945723B (zh) * 2021-10-28 2024-03-12 复旦大学附属中山医院 预测免疫检查点抑制剂治疗相关肺炎发生风险的系统、储存介质及其应用
CN117899200B (zh) * 2022-10-18 2025-11-07 华中科技大学 用于增强免疫治疗疗效的药物及其治疗肿瘤之应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PL2904011T3 (pl) * 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
EP3137105A4 (en) * 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CA2955612C (en) * 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
DK3303396T5 (da) * 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
CA3084370A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "FDA APPROVES KEYTRUDA (PEMBROLIZUMAB) FOR THE TREATMENT OF PATIENTS WITH METASTATIC 以下備考", MERCK, JPN5019002036, 2 October 2015 (2015-10-02), pages 1 - 4, ISSN: 0004577176 *
J. ZHANG: "P2.01-097 - Phase 3 Study of Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC (ID2182)", IASLC, WCLC 2015, JPN5019002038, 2015, pages 1 - 2, ISSN: 0004577175 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol. 33, No. 15 suppl, JPN6021001809, 20 May 2015 (2015-05-20), pages 8011, ISSN: 0004577177 *

Also Published As

Publication number Publication date
US20230083487A1 (en) 2023-03-16
US20210206854A1 (en) 2021-07-08
WO2017132508A1 (en) 2017-08-03
JP2022046649A (ja) 2022-03-23
EP3408296A1 (en) 2018-12-05
CN108602892A (zh) 2018-09-28
JP2024133611A (ja) 2024-10-02
US20260092114A1 (en) 2026-04-02
KR20180101584A (ko) 2018-09-12

Similar Documents

Publication Publication Date Title
US20260092114A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20250154274A1 (en) Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
US20250011466A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20210000953A1 (en) Use of immune checkpoint inhibitors in central nervous systems neoplasms
KR102636539B1 (ko) 암에 대한 조합 요법
TWI912619B (zh) 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌
JP2024063023A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置
BR112014028826B1 (pt) Uso de nivolumab ou pembrolizumabe
KR20190015407A (ko) 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
EP4204453A1 (en) Cell localization signature and immunotherapy
JP2023093514A (ja) 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ－１抗体組合せ併用療法
TW202604568A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌
BR122024000362A2 (pt) Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210824